207 related articles for article (PubMed ID: 33047189)
1. Effect of etelcalcetide on parathyroid hormone secretion by primary hyperparathyroidism patient-derived primary parathyroid cells.
Fujioka A; Imanishi Y; Kobayashi I; Hirakawa T; Inoue A; Harada K; Taguchi M; Sugiura Y; Yamada H; Miyaoka D; Hayashi N; Emoto M; Inaba M
J Bone Miner Metab; 2021 May; 39(3):396-403. PubMed ID: 33047189
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of Parsabiv
Harada K; Fujioka A; Konno M; Inoue A; Yamada H; Hirota Y
Eur J Pharmacol; 2019 Jan; 842():139-145. PubMed ID: 30342948
[TBL] [Abstract][Full Text] [Related]
3. Etelcalcetide decreases the PTH-calcium setpoint without changing maximum and minimum PTH secretion in mice with primary hyperparathyroidism.
Hayashi N; Imanishi Y; Hirakawa T; Kobayashi I; Tateishi T; Miyaoka D; Nagata Y; Mori K; Morioka T; Inoue A; Harada K; Inaba M; Emoto M
J Bone Miner Metab; 2021 May; 39(3):430-438. PubMed ID: 33196900
[TBL] [Abstract][Full Text] [Related]
4. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
[TBL] [Abstract][Full Text] [Related]
5. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients.
Fukagawa M; Yokoyama K; Shigematsu T; Akiba T; Fujii A; Kuramoto T; Odani M; Akizawa T;
Nephrol Dial Transplant; 2017 Oct; 32(10):1723-1730. PubMed ID: 28057872
[TBL] [Abstract][Full Text] [Related]
6. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
7. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
Block GA; Bushinsky DA; Cunningham J; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Mix TC; Moe SM; Patel UD; Silver J; Spiegel DM; Sterling L; Walsh L; Chertow GM
JAMA; 2017 Jan; 317(2):146-155. PubMed ID: 28097355
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.
Chen P; Narayanan A; Wu B; Gisleskog PO; Gibbs JP; Chow AT; Melhem M
Clin Pharmacokinet; 2018 Jan; 57(1):71-85. PubMed ID: 28508378
[TBL] [Abstract][Full Text] [Related]
9. Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism.
Yu L; Tomlinson JE; Alexander ST; Hensley K; Han CY; Dwyer D; Stolina M; Dean C; Goodman WG; Richards WG; Li X
Calcif Tissue Int; 2017 Dec; 101(6):641-653. PubMed ID: 29038882
[TBL] [Abstract][Full Text] [Related]
10. Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism.
Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Shinoda A; Akizawa T
Nephrology (Carlton); 2020 Aug; 25(8):634-643. PubMed ID: 31765028
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis.
Wu B; Melhem M; Subramanian R; Chen P; Jaramilla Sloey B; Fouqueray B; Hock MB; Skiles GL; Chow AT; Lee E
J Clin Pharmacol; 2018 Jun; 58(6):717-726. PubMed ID: 29534286
[TBL] [Abstract][Full Text] [Related]
12. Nonclinical Safety Profile of Etelcalcetide, a Novel Peptide Calcimimetic for the Treatment of Secondary Hyperparathyroidism.
Fielden MR; Dean C; Black K; Sawant SG; Subramanian R; Tomlinson JE; Walter S; Zimmermann C; Griggs MW; McKeon ME; Lewis EM; Beevers C; Pyrah I
Int J Toxicol; 2016 May; 35(3):294-308. PubMed ID: 26941242
[TBL] [Abstract][Full Text] [Related]
13. Etelcalcetide: First Global Approval.
Blair HA
Drugs; 2016 Dec; 76(18):1787-1792. PubMed ID: 27900648
[TBL] [Abstract][Full Text] [Related]
14. Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels.
Kawata T; Imanishi Y; Kobayashi K; Onoda N; Okuno S; Takemoto Y; Komo T; Tahara H; Wada M; Nagano N; Ishimura E; Miki T; Ishikawa T; Inaba M; Nishizawa Y
J Bone Miner Metab; 2006; 24(4):300-6. PubMed ID: 16816924
[TBL] [Abstract][Full Text] [Related]
15. A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients
.
Yokoyama K; Fukagawa M; Shigematsu T; Akiba T; Fujii A; Odani M; Akizawa T
Clin Nephrol; 2017 Aug; 88(2):68-78. PubMed ID: 28671062
[TBL] [Abstract][Full Text] [Related]
16. Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore.
Khan BA; Qu X; Hua Y; Javaid MM
Cureus; 2023 Nov; 15(11):e48186. PubMed ID: 38050530
[TBL] [Abstract][Full Text] [Related]
17. Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients.
Cunningham J; Block GA; Chertow GM; Cooper K; Evenepoel P; Iles J; Sun Y; Ureña-Torres P; Bushinsky DA
Kidney Int Rep; 2019 Jul; 4(7):987-994. PubMed ID: 31317120
[TBL] [Abstract][Full Text] [Related]
18. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.
Bushinsky DA; Chertow GM; Cheng S; Deng H; Kopyt N; Martin KJ; Rastogi A; Ureña-Torres P; Vervloet M; Block GA
Nephrol Dial Transplant; 2020 Oct; 35(10):1769-1778. PubMed ID: 30859218
[TBL] [Abstract][Full Text] [Related]
19. Stimulating parathyroid cell proliferation and PTH release with phosphate in organ cultures obtained from patients with primary and secondary hyperparathyroidism for a prolonged period.
Nakajima K; Umino K; Azuma Y; Kosaka S; Takano K; Obara T; Sato K
J Bone Miner Metab; 2009; 27(2):224-33. PubMed ID: 19194773
[TBL] [Abstract][Full Text] [Related]
20. Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study.
Mima A; Tansho K; Nagahara D; Watase K
J Int Med Res; 2018 Nov; 46(11):4578-4585. PubMed ID: 30027791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
